Human APOBEC3 Induced Mutation of Human Immunodeficiency Virus Type-1 Contributes to Adaptation and Evolution in Natural Infection

PLoS Pathogens

Volumn 10, Issue 7, 2014, Pages

  Kim, Eun Young ^a   Lorenzo Redondo, Ramon ^a   Little, Susan J ^b   Chung, Yoon Seok ^a   Phalora, Prabhjeet K ^c   Maljkovic Berry, Irina ^a   Archer, John ^d   Penugonda, Sudhir ^a   Fischer, Will ^e   Richman, Douglas D ^b,f   Bhattacharya, Tanmoy ^e,g   Malim, Michael H ^c   Wolinsky, Steven M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g SANTA FE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3 PROTEIN, HUMAN; APOBEC3D PROTEIN, HUMAN; APOBEC3F PROTEIN, HUMAN; APOBEC3G PROTEIN, HUMAN; APOBEC3H PROTEIN, HUMAN; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HYDROLASE; VIRUS DNA;

ADAPTATION; EVOLUTION; GENETIC VARIABILITY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; VIROLOGY; VIRUS GENOME; VIRUS REPLICATION;

ADAPTATION, PHYSIOLOGICAL; AMINOHYDROLASES; BASE SEQUENCE; BIOLOGICAL EVOLUTION; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA, VIRAL; GENETIC VARIATION; GENOME, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, NUCLEIC ACID; VIRUS REPLICATION;

EID: 84905399319     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004281     Document Type: Article

References (68)

1. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
2. Mansky LM, Temin HM, (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
3. Peeters M, Sharp PM, (2000) Genetic diversity of HIV-1: the moving target. AIDS 14 Suppl 3: S129-140.
4. Steinhauer DA, Domingo E, Holland JJ, (1992) Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122: 281-288.
5. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
6. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S, (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34: 4677-4684.
7. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32: 2421-2429.
8. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442.
9. Goila-Gaur R, Strebel K, (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5: 51.
10. Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, et al. (2014) Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol 426: 1220-1245.
11. Holmes RK, Malim MH, Bishop KN, (2007) APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 32: 118-128.
12. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392-1396.
13. Liddament MT, Brown WL, Schumacher AJ, Harris RS, (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14: 1385-1391.
14. Arias JF, Koyama T, Kinomoto M, Tokunaga K, (2012) Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. Front Microbiol 3: 275.
15. Chiu YL, Greene WC, (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26: 317-353.
16. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, et al. (2012) Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481: 371-375.
17. Malim MH, (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364: 675-687.
18. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
19. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
20. Janini M, Rogers M, Birx DR, McCutchan FE, (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 75: 7973-7986.
21. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, et al. (2010) Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 84: 10402-10405.
22. Jern P, Russell RA, Pathak VK, Coffin JM, (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog 5: e1000367.
23. Mulder LC, Harari A, Simon V, (2008) Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A 105: 5501-5506.
24. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
25. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1: e6.
26. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, et al. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J Virol 87: 1508-1517.
27. Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, et al. (2010) The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med 207: 39-49.
28. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, et al. (2008) Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol 82: 8743-8761.
29. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, et al. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85: 11220-11234.
30. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR, (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. The EMBO Journal 23: 2451-2458.
31. Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, et al. (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One 5: e12303.
32. Acevedo A, Brodsky L, Andino R, (2014) Mutational and fitness landscapes of an RNA virus revealed through population sequencing. Nature 505: 686-690.
33. Armitage AE, Deforche K, Chang CH, Wee E, Kramer B, et al. (2012) APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet 8: e1002550.
34. Le T, Wright EJ, Smith DM, He W, Catano G, et al. (2013) Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 368: 218-230.
35. Harari A, Ooms M, Mulder LC, Simon V, (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol 83: 295-303.
36. Li MM, Emerman M, (2011) Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity. J Virol 85: 8197-8207.
37. Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, et al. (2013) HIV-1 Vif Adaptation to Human APOBEC3H Haplotypes. Cell Host Microbe 14: 411-421.
38. Wang X, Abudu A, Son S, Dang Y, Venta PJ, et al. (2011) Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol 85: 3142-3152.
39. Zhen A, Du J, Zhou X, Xiong Y, Yu XF, (2012) Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS One 7: e38771.
40. Eriksson N, Pachter L, Mitsuya Y, Rhee SY, Wang C, et al. (2008) Viral population estimation using pyrosequencing. PLoS Comput Biol 4: e1000074.
41. Anisimova M, Gascuel O, (2006) Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative. Syst Biol 55: 539-552.
42. Korber B (2000) HIV Signature and Sequence Variation Analysis. Computational Analysis of HIV Molecular Sequences. Allen G. Rodrigo and Gerald HLearn, eds. ed. Dordrecht, Netherlands: Kluwer Academic Publishers. pp. 55-72.
43. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, et al. (2000) Timing the ancestor of the HIV-1 pandemic strains. Science 288: 1789-1796.
44. Leitner T, Albert J, (1999) The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc Natl Acad Sci U S A 96: 10752-10757.
45. Maljkovic Berry I, Athreya G, Kothari M, Daniels M, Bruno WJ, et al. (2009) The evolutionary rate dynamically tracks changes in HIV-1 epidemics: application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. Epidemics 1: 230-239.
46. Gould SJ, (1970) Dollo on Dollo's law: irreversibility and the status of evolutionary laws. J Hist Biol 3: 189-212.
47. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, et al. (2005) Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79: 13239-13249.
48. Ferrari G, Korber B, Goonetilleke N, Liu MK, Turnbull EL, et al. (2011) Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog 7: e1001273.
49. McMichael AJ, Rowland-Jones SL, (2001) Cellular immune responses to HIV. Nature 410: 980-987.
50. Pond SL, Frost SD, (2005) Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21: 2531-2533.
51. Mbisa JL, Bu W, Pathak VK, (2010) APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol 84: 5250-5259.
52. Ara A, Love RP, Chelico L, (2014) Different Mutagenic Potential of HIV-1 Restriction Factors APOBEC3G and APOBEC3F Is Determined by Distinct Single-Stranded DNA Scanning Mechanisms. PLoS Pathog 10: e1004024.
53. Vartanian JP, Henry M, Marchio A, Suspene R, Aynaud MM, et al. (2010) Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 6: e1000928.
54. Pollom E, Dang KK, Potter EL, Gorelick RJ, Burch CL, et al. (2013) Comparison of SIV and HIV-1 genomic RNA structures reveals impact of sequence evolution on conserved and non-conserved structural motifs. PLoS Pathog 9: e1003294.
55. Malim MH, Emerman M, (2001) HIV-1 sequence variation: drift, shift, and attenuation. Cell 104: 469-472.
56. Phalora PK, Sherer NM, Wolinsky SM, Swanson CM, Malim MH, (2012) HIV-1 Replication and APOBEC3 Antiviral Activity Are Not Regulated by P Bodies. J Virol 86: 11712-11724.
57. Moonsamy PV, Williams T, Bonella P, Holcomb CL, Hoglund BN, et al. (2013) High throughput HLA genotyping using 454 sequencing and the Fluidigm Access Array System for simplified amplicon library preparation. Tissue Antigens 81: 141-149.
58. Foley B LT, Apetrei C, Hahn B, Mizrachi I, Mullins J, Rambaut A, Wolinsky S, and Korber B, editor (2013) HIV Sequence Compendium. Los Alamos, New Mexico: Theoretical Biology and Biophysics Group.
59. Archer J, Baillie G, Watson SJ, Kellam P, Rambaut A, et al. (2012) Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics 13: 47.
60. Pearson WR, Lipman DJ, (1988) Improved tools for biological sequence comparison. Proc Natl Acad Sci U S A 85: 2444-2448.
61. Edgar RC, (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792-1797.
62. Guindon S, Gascuel O, (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696-704.
63. Kosakovsky Pond SL, Frost SD, (2005) Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 22: 1208-1222.
64. Drummond AJ, Suchard MA, Xie D, Rambaut A, (2012) Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol 29: 1969-1973.
65. Holcomb CL, Hoglund B, Anderson MW, Blake LA, Bohme I, et al. (2011) A multi-site study using high-resolution HLA genotyping by next generation sequencing. Tissue Antigens 77: 206-217.
66. Yusim K, Korber, B. T. M., Brander C, Haynes BF, Koup, R, Moore JP, Walker, BD and Watkins, DI, editor (2009) HIV Molecular Immunology. Los Alamos, New Mexico: Los Alamos National Laboratory, Theoretical Biology and Biophysics.
67. R Development Core Team (2013) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
68. Dorai-Raj S (2014) binom: Binomial Confidence Intervals For Several Parameterizations. version 1.1-1 ed. http://CRAN.R-project.org/package=binom.